MiNK Therapeutics (INKT) Regains Nasdaq Compliance

MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases, today announced that it has received formal notice from Nasdaq confirming that the Company has regained compliance with both the minimum bid price and market value of listed securities requirements for continued listing on The Nasdaq Capital Market. As a result, MiNK now meets all Nasdaq Capital Market listing requirements, and the matter has been closed.

You May Also Be Interested In

• Pizza Hut CEO Aaron Powell resigns
• Methanex to idle New Zealand plants in 2027, sells gas rights
• Biosenta signs MOU with Dynamic Facility Services for disinfectant pilot